Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00174720 | Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid. | PHASE3 | COMPLETED | 708 | — | — | Sep 1, 2005 | Feb 1, 2007 | Apr 8, 2009 | 11 | United States, Brazil +9 |
| NCT00174733 | Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid | PHASE3 | COMPLETED | 456 | — | — | Jul 1, 2005 | Feb 1, 2006 | Apr 8, 2009 | 1 | United States |
| NCT00270348 | Effects of Ciclesonide MDI 50mg/Day and 200mg/Day (Ex-Valve) Once-Daily on Growth in Children With Mild Persistent Asthma | PHASE3 | COMPLETED | 450 | — | — | Dec 1, 2000 | Sep 1, 2004 | Dec 28, 2005 | - | — |
| Name | Type | Description |
|---|---|---|
| Ciclesonide (XRP1526) | DRUG | - |
| ciclesonide | DRUG | - |
Inclusion Criteria: * Males or females 12 years or older * History of persistent bronchial asthma for at least 6 months * Documented use of bronchodilators (short acting only) only or methylxanthines for at least 1 month before screening * At screening, FEV1 60 to 90% of predicted. Reversibility of...